Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
复制标题
转移性和局部晚期乳腺癌患者连续输注氟尿嘧啶联合表柔比星和顺铂的 II 期研究：一种积极的新方案。
DOI：
--
复制
发表时间：
1994
影响因子：
45.3
通讯作者：
S. Ashley
中科院分区：
文献类型：
--
作者：
A. Jones;I. Smith;M. O'Brien;D. Talbot;G. Walsh;F. Ramage;H. Robertshaw;S. Ashley
目的
目的观察5-氟尿嘧啶(5-FU)持续滴注联合表阿霉素和顺铂(ECF)治疗晚期乳腺癌的疗效和毒性。
患者和方法
43例转移性乳腺癌(n=29)或局部晚期/炎症性乳腺癌(n=14)用5-FU 200 mg/m~2/d经希克曼静脉输注，静脉滴注表阿霉素50 mg/m~2，顺铂60 mg/m~2，每3周一次，共8个疗程，疗程6个月。
结果
总有效率(完全+部分)为84%(95%可信区间，76%~96%)，转移性疾病患者完全缓解率为24%(95%CI，9%~40%)，局部晚期患者完全缓解率为36%(95%CI，11%~61%)。主要的世界卫生组织[WHO]3级或4级毒性包括白细胞减少、呕吐和脱发。
结论
静脉注射ECF是治疗晚期乳腺癌的一种高效方案，值得对高危早期乳腺癌进行评估。
PURPOSE
To investigate the efficacy and toxicity of continuous infusion fluorouracil (5-FU) with every-3-weeks epirubicin and cisplatin (ECF) in advanced breast cancer in a phase II study.
PATIENTS AND METHODS
Forty-three patients with metastatic (n = 29) or locally advanced/inflammatory (n = 14) breast cancer were treated with 5-FU 200 mg/m2/d via a Hickman line using an ambulatory pump for 6 months with epirubicin 50 mg/m2 intravenously (IV) and cisplatin 60 mg/m2 IV every 3 weeks, for eight courses.
RESULTS
The overall response rate (complete plus partial) was 84% (95% confidence interval [Cl], 76% to 96%), with a complete response rate of 24% (95% Cl, 9% to 40%) in patients with metastatic disease and 36% (95% Cl, 11% to 61%) in patients with locally advanced disease. The main World Health Organization [WHO] grade 3 or 4 toxicities included leukopenia, emesis, and alopecia.
CONCLUSION
Infusional ECF is a highly active regimen in advanced breast cancer and warrants evaluation in high-risk early breast cancer.
影响因子：
45.3
作者：
SLEDGE, GW;LOEHRER, PJ;EINHORN, LH
通讯作者：
EINHORN, LH